RxDoctor Payments Data

Siddhartha Kattamanchi, MD

Nephrology · Marshfield, WINPI 1316388382

Payments from drug & device makers

What this record shows

3 manufacturers reported payments, led by Travere Therapeutics, Inc. at 52.3% of the total. 2022 is the largest year on record at $123, 7.4 times the $17 reported in 2019. That places this record below the midpoint for nephrology clinicians in WI, where the typical reported total is $267.

$235in general payments, 2019–2025

Across 3 payments — averaging $78.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$123
  • Otsuka America Pharmaceutical, Inc.$96
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$17
$201,370in research payments, 2019–2025

Across 154 payments — averaging $1307.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Travere Therapeutics, Inc.$128K
  • Boehringer Ingelheim$42K
  • Novartis$28K
  • Boehringer Ingelheim International GmbH$3K

What the payments were for

  • Food & beverage$12352%
  • Education$11248%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$235 in reported general payments places this provider in the 45th percentile of 173 nephrology providers in Wisconsin.

See all nephrology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$48,596
Medicare patients
163
Services billed
583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan13$251,027
JardianceEmpagliflozin11$5,831
TazicefCeftazidime25$484
Ceftazidime21$453
Enalapril Maleate11$414
Calcitriol32$283
Furosemide35$257
Amlodipine Besylate49$238
Losartan Potassium43$216
Lisinopril21$139
Spironolactone15$128
Prednisone21$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$96$251,02713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 173 nephrology providers in Wisconsin.

Other nephrology in Marshfield

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →